Drug Trial Radar · NCT03759665
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
Last checked: Nov 20, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jun 7, 2019
Primary completion
Jan 9, 2023
Study completion Jan 9, 2023
Sponsor
- Lead sponsor
- IntraBio IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease). There are two phases to this study: the Parent Study, and the Extension Phase. The Parent Study evaluates the safety and efficacy of N-Acetyl-L-Leucine (IB1001) in the symptomatic treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease). The Extension Phase evaluates the long-term safety and efficacy of IB1001 for the neuroprotective, disease-modifying treatment of GM2 Gangliosidosis. The Extension Phase was considered exploratory.
Conditions
- GM2 Gangliosidosis
- Tay-Sachs Disease
- Sandhoff Disease
Interventions
IB1001Drug
IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Impression of Change in Severity (CI-CS) [Fields et al 2021]Time frame: (CI-CS comparing Baseline [Day 1] with IB1001 versus the end of 6-weeks treatment with IB1001 [approximately Day 42]) MINUS (CI-CS comparing the end of 6-weeks treatment with IB1001 [approximately Day 42] versus end of 6-weeks post-treatment washout);
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
University of California - Los Angeles
Los Angeles, California
Mayo Clinic
Rochester, Minnesota
NYU Langone School of Medicine
New York, New York
University of Giessen
Giessen, Germany
Ludwig Maximilian University of Munich
München, Germany
Bellvitge University Hospital
Barcelona, Spain
Royal Manchester Children's Hospital
Manchester, United Kingdom
Salford Trust
Salford, Greater Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.